Sonnet Biotherapeutics is a biotechnology business based in the US. Sonnet Biotherapeutics shares (SONN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.36 – a decrease of 8.72% over the previous week. Sonnet Biotherapeutics employs 13 staff and has a trailing 12-month revenue of around $1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.36 |
|---|---|
| 52-week range | $1.10 - $16.00 |
| 50-day moving average | $1.37 |
| 200-day moving average | $3.47 |
| Wall St. target price | $20.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-10.45 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.36 from 2025-05-02
| 1 week (2025-04-25) | -0.73% |
|---|---|
| 1 month (2025-04-04) | 8.80% |
| 3 months (2025-02-05) | -17.07% |
| 6 months (2024-11-05) | -67.70% |
| 1 year (2024-05-03) | -26.90% |
|---|---|
| 2 years (2023-05-04) | -96.79% |
| 3 years (2022-05-04) | 749.3029 |
| 5 years (2020-05-05) | 11802.56 |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $-351,390 |
| Return on assets TTM | -133.99% |
| Return on equity TTM | -285.35% |
| Profit margin | 0% |
| Book value | $1.34 |
| Market Capitalization | $4.3 million |
TTM: trailing 12 months
We're not expecting Sonnet Biotherapeutics to pay a dividend over the next 12 months.
Sonnet Biotherapeutics's shares were split on a 1:8 basis on 29 September 2024 . So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonnet Biotherapeutics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Sonnet Biotherapeutics shares which in turn could have impacted Sonnet Biotherapeutics's share price.
Over the last 12 months, Sonnet Biotherapeutics's shares have ranged in value from as little as $1.1 up to $16. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sonnet Biotherapeutics's is 0.987. This would suggest that Sonnet Biotherapeutics's shares are less volatile than average (for this exchange).
Sonnet BioTherapeutics Holdings, Inc. , a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .